pj devereaux, population health research institute, hamilton, canada
DESCRIPTION
POISE-2. P eri O perative IS chemic E valuation- 2 Trial. Aspirin in Patients Undergoing Noncardiac Surgery. PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators. Background. Worldwide 200 million adults have noncardiac surgery annually - PowerPoint PPT PresentationTRANSCRIPT
PJ Devereaux, Population Health Research Institute, Hamilton, Canada
on behalf of POISE-2 Investigators
PeriOperative ISchemic Evaluation-2 Trial
POISE-2POISE-2POISE-2POISE-2
Aspirin in Patients Undergoing Noncardiac Surgery
Background
2
• Worldwide 200 million adults have noncardiac surgery annually • 10 million suffer major vascular complication
• MI is most common• Surgery – associated with platelet activation
• thrombosis may be mechanism of periop MI• Substantial variability in periop usage of aspirin
• aspirin-naive pts and pts taking aspirin chronically
Methods
3
• Design – blinded RCT, 135 centres in 23 countries • Eligibility criteria –undergoing noncardiac surgery,
≥45 yrs, at risk of vascular complication• Recruitment –10,010 pts, July 2010 to Dec 2013 • 2 aspirin strata - Starting Stratum (n=5628),
Continuation Stratum (n=4382)• Intervention - aspirin/placebo (200 mg) just
before surgery; continued daily (100 mg) 30 days in Starting and 7 days in Continuation Stratum
• Primary outcome: composite of death and nonfatal MI at 30 days
Results
4
Outcome Aspirin(4998)
Placebo(5012)
HR (95% CI)
P
1O outcome:death or MI 351 (7.0) 355 (7.1)
0.99 (0.86-1.15) 0.92
2O outcome:death, MI, or strokedeath, MI, revasc, or VTE
362 (7.2)
402 (8.0)
370 (7.4)
407 (8.1)
0.98 (0.85-1.13)
0.99 (0.86-1.14)
0.80
0.90
3O outcomes:MI 309 (6.2) 315 (6.3) 0.98 (0.84-1.15) 0.85
safety outcomeMajor bleeding 229 (4.6) 187 (3.7) 1.23 (1.01-1.49) 0.04
Results• Primary and 2nd outcome results similar in both
aspirin strata• 65% of patients received prophylactic anticoag• Multivariable regression – life-threatening or
major bleed independent predictor of periop MI– HR, 1.82; (95% CI, 1.40-2.36); P<0.001
• Post-hoc analyses suggest– 1.0-1.3% absolute increase in life-threatening or
major bleeding if aspirin started within 2 days after Sx• risk decreases to 0.3% if started on day 8 after surgery 5
Conclusions
6
• Perioperative aspirin did not prevent • death or MI but increased risk of major bleeding
• Primary and 2nd outcome results consistent • both aspirin strata
• Life-threatening and major bleeding • independent predictor of MI
• Optimal time to restart aspirin • 8 – 10 days after surgery